Takeda Pharmaceutical Co. Ltd.'s Fiscal Year is From April To March - All Figures are in JPY, Billions.
The item "Depreciation-and-Amortization-Expense" stands at 743.34 Billion Japanese Yens for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 06/30/2024.
Takeda Pharmaceutical Co. Ltd.'s second quarter result of 184.98 Billion JPY for the item "Depreciation and Amortization Expense" represents an increase of 1.84 percent compared to it's first quarter result.
Also, Takeda Pharmaceutical Co. Ltd.'s second quarter result of 184.98 Billion JPY for the item "Depreciation and Amortization Expense" represents a decrease of -3.88 percent compared to it's second quarter result of last year.
Looking again at the trailing twelve months series (TTM), Takeda Pharmaceutical Co. Ltd.'s second quarter result of 743.34 Billion JPY for the item "Depreciation and Amortization Expense" represents a decrease of -0.99 percent compared to it's first quarter result.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -2.00 percent compared to the value the year prior.
The 1 year change in percent is -2.00.
The 3 year change in percent is 18.81.
The 5 year change in percent is 42.35.
The 10 year change in percent is 187.83.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Depreciation and Amortization Expense | 905,699,262,464.00 |
![]() | Johnson & Johnson - Depreciation and Amortization Expense | 486,508,953,600.00 |
![]() | AbbVie Inc - Depreciation and Amortization Expense | 399,570,305,024.00 |
![]() | Roche Holding AG - Depreciation and Amortization Expense | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Depreciation and Amortization Expense | 280,205,508,085.11 |